Rio.ai Raises ₹43 Crore Led by Version One Ventures to Scale WhatsApp-Based 30-Minute Medicine Delivery

Rio.ai, a healthtech startup building an artificial-intelligence-powered quick-commerce platform for medicines and healthcare essentials, has raised ₹43.08 crore in a pre-Series A funding round led by new investor Version One Ventures, according to regulatory filings reported by Entrackr on Wednesday, September 23.

Existing investors Xeed Ventures, Good Capital and Amplify Partner also participated in the round.

Rio.ai’s board approved the allotment of 7,130 compulsorily convertible preference shares at an issue price of ₹60,415 per share to raise the amount, the filings showed. Version One Ventures invested ₹21.30 crore, followed by Xeed Ventures with ₹11.84 crore, Good Capital Fund II with ₹9.47 crore and Amplify IV PCC with ₹47 lakh.

Entrackr estimated the company’s post-money valuation at around ₹170 crore.

Medicines via WhatsApp in under 30 minutes

Founded by Ankur Agrawal and Amit Ahuja, Rio.ai operates Rio Health, a platform that allows users to order medicines and other healthcare products through WhatsApp, with deliveries in 15 to 30 minutes.

The model combines three of the most prominent themes in Indian consumer technology: quick commerce, conversational interfaces and artificial intelligence. Instead of downloading a dedicated app, customers message the service on WhatsApp — already installed on hundreds of millions of Indian smartphones — to place orders, share prescriptions and receive updates.

AI plays a role in making that conversational experience work at scale. Automated systems can interpret messages, identify products, process prescriptions and manage order flows, reducing the need for human intervention in each interaction while keeping the experience conversational for the user.

Why speed matters in pharmacy

Quick commerce has transformed grocery shopping in India’s major cities, with companies promising deliveries in 10 to 20 minutes from networks of small, strategically located warehouses. Medicines represent a natural extension of that model, but with important differences.

For many healthcare purchases, speed is not a convenience but a necessity — a parent looking for fever medication late at night, a patient who has run out of a regular prescription, or a family caring for an elderly relative. A reliable 15-to-30-minute delivery window can make a meaningful difference in those situations.

At the same time, pharmacy is more complex than groceries. Sales of prescription medicines are regulated, requiring valid prescriptions and licensed pharmacists. Inventory must be managed carefully, with attention to expiry dates, storage conditions and a long tail of products. And customers need confidence in the authenticity of what they receive.

The WhatsApp advantage

Using WhatsApp as the primary interface is a deliberate choice for the Indian market. Many consumers, particularly older users and those in smaller cities, are more comfortable messaging than navigating a dedicated app. For a startup, the approach also reduces the cost of acquiring customers, because it removes the friction of persuading users to download, register and learn a new application.

The trade-off is dependence on a third-party platform. Businesses that operate on WhatsApp are subject to Meta’s commercial terms, messaging costs and policy changes. Rio.ai will need to balance the reach and familiarity of WhatsApp with its own ability to build a direct, defensible relationship with customers.

Ownership after the round

Following the latest allotment, Xeed Ventures holds a 21.11% stake in Rio.ai, Good Capital holds 17.07% and Version One Ventures owns 12.86%, according to Entrackr. Co-founders Ankur Agrawal and Amit Ahuja hold 17.50% each.

The founders’ combined 35% stake after a pre-Series A round suggests that they retain meaningful ownership as they head towards larger fundraises — an important consideration for founder incentives in a capital-intensive sector.

The company said the fresh capital would be used to meet general operating and working-capital requirements, fund capital expenditure, strengthen its capital base and support the expansion of its business operations.

An investor lens

Version One Ventures, which led the round, is an early-stage firm known for backing network-driven and technology-led businesses. Its decision to lead the round as a new investor adds external validation to a model that existing backers Xeed Ventures and Good Capital had supported from earlier stages.

The round also follows earlier market reports about the company’s fundraising plans. Moneycontrol had reported that Rio.ai was in talks to raise around $5 million from investors including Binny Bansal and Canada-based funds, according to Entrackr. The filings reported on Wednesday confirm the investors that ultimately participated in this pre-Series A tranche.

A competitive market

Rio.ai is entering a crowded field. Established e-pharmacies have built large national operations, while quick-commerce platforms have added healthcare and wellness categories to their grocery offerings. Offline pharmacies remain the dominant channel, supported by deep local relationships and immediate availability.

To succeed, Rio.ai will need to show that its combination of WhatsApp-based ordering and rapid delivery creates enough customer loyalty to overcome the scale advantages of larger players. Key metrics will include repeat purchase rates, order values, delivery reliability and the economics of each dark store or fulfilment point.

The broader healthtech sector in India has seen a more cautious funding environment in recent years, with investors focusing on companies that can demonstrate a clear path to profitability. Rio.ai’s pre-Series A round suggests that investors see promise in a lean, conversational model that avoids some of the customer-acquisition costs associated with app-based platforms.

What comes next

With ₹43 crore in fresh capital, Rio.ai has room to deepen inventory, expand fulfilment capacity and invest in the AI systems that underpin its WhatsApp interface. The company’s ability to convert that investment into dense local networks — where fast delivery is consistently achievable at acceptable cost — will likely determine the size of its next round.

If the model works, it could offer a blueprint for how conversational commerce can be applied to regulated, high-trust categories in India. For patients and families, the promise is simple: essential medicines delivered quickly, ordered through an app they already use every day.

Health-focused quick commerce also carries a public-interest dimension. Faster access to genuine medicines, combined with proper prescription checks, can improve outcomes in urgent situations — provided that speed never comes at the expense of regulatory compliance and patient safety.